Evidence map›Paper›PMID 35711345›Full record

ArticleFrontiers in cardiovascular medicine2022

Additive Impact of Interleukin 6 and Neuron Specific Enolase for Prognosis in Patients With Out-of-Hospital Cardiac Arrest - Experience From the HAnnover COoling REgistry.

Muharrem Akin, Jan-Thorben Sieweke, Vera Garcheva, Carolina Sanchez Martinez, John Adel, Pia Plank, Paris Zandian, Kurt-Wolfram Sühs, Johann Bauersachs, Andreas Schäfer

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Cytokine hemoadsorption with CytoSorbCritical care (London, England) · 2023
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Muharrem AkinCardiac Arrest Center, Department of Cardiology and Angiology, Hannover Medical School, Hanover, Germany.
Jan-Thorben SiewekeCardiac Arrest Center, Department of Cardiology and Angiology, Hannover Medical School, Hanover, Germany.
Vera GarchevaCardiac Arrest Center, Department of Cardiology and Angiology, Hannover Medical School, Hanover, Germany.
Carolina Sanchez MartinezCardiac Arrest Center, Department of Cardiology and Angiology, Hannover Medical School, Hanover, Germany.
John AdelCardiac Arrest Center, Department of Cardiology and Angiology, Hannover Medical School, Hanover, Germany.
Pia PlankCardiac Arrest Center, Department of Cardiology and Angiology, Hannover Medical School, Hanover, Germany.
Paris ZandianCardiac Arrest Center, Department of Cardiology and Angiology, Hannover Medical School, Hanover, Germany.
Kurt-Wolfram SühsDepartment of Neurology, Hannover Medical School, Hanover, Germany.
Johann BauersachsCardiac Arrest Center, Department of Cardiology and Angiology, Hannover Medical School, Hanover, Germany.
Andreas SchäferCardiac Arrest Center, Department of Cardiology and Angiology, Hannover Medical School, Hanover, Germany.
Medizinische Hochschule Hannover · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients after out-of-hospital cardiac arrest (OHCA) are at increased risk for mortality and poor neurological outcome. We assessed the additive impact of interleukin 6 (IL-6) at admission to neuron-specific enolase (NSE) at day 3 for prognosis of 30-day mortality and long-term neurological outcome in OHCA patients. Methods: A total of 217 patients from the HAnnover COoling REgistry with return of spontaneous circulation (ROSC) after OHCA and IL-6 measurement immediately after admission during 2017-2020 were included to investigate the prognostic value and importance of IL-6 in addition to NSE obtained on day 3. Poor neurological outcome was defined by cerebral performance category (CPC) ≥ 3 after 6 months. Results: Patients with poor outcome showed higher IL-6 values (30-day mortality: 2,224 ± 524 ng/l vs 186 ± 15 ng/l, Conclusion: Elevated IL-6 levels at admission after ROSC were closely associated with 30-day mortality. The combination of IL-6 and NSE provided clinically important additive information for predict poor neurological outcome at 6 months.

Indexed as

interleukin 6neurological outcomeneuron-specific enolaseout-of-hospital cardiac arrestprognosis

Identifiers

PMID35711345
PMCPMC9194609
OpenAlexW4281636570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.